<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412625/" ref="ordinalpos=383&amp;ncbi_uid=5144615&amp;link_uid=PMC3412625" image-link="/pmc/articles/PMC3412625/figure/F6/" class="imagepopup">Figure 6. Schematic representation of potential effects of VELCADE on TLR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>.  From: Combination therapy with VELCADE and tPA is neuroprotective in aged rats after stroke and targets miRNA-146a and the toll-like receptor <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">Stroke induces the activation of vascular TLR signal, which leads to upregulation of proinflammatory genes via the activation of NF-ÎºB. VELCADE inactivates NF-kB through either directly blocking stroke-activated TLR2 and TLR4 or indirectly repressing IRAK1 by VELCADE upregulated miR-146a, which consequently downregulates proinflammatory gene expression. Thus, VELCADE acts on a multi-level inhibition of TLR signaling in ischemic cerebral vessels.</div></div>